Cervical cancer and use of hormonal contraceptives: A systematic review

Lancet

Volumn 361, Issue 9364, 2003, Pages 1159-1167

  Smith, Jennifer S ^a   Green, Jane ^b   Berrington De Gonzalez, Amy ^b   Appleby, Paul ^b   Peto, Julian ^c,d   Plummer, Martyn ^a   Franceschi, Silvia ^a   Beral, Valerie ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADENOCARCINOMA; ARTICLE; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CARCINOMA IN SITU; HORMONAL CONTRACEPTION; HUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; SEXUALITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0037420509     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12949-2     Document Type: Article

References (48)

1. Ferlay J., Parkin D.M., Pisani P. GLOBOCAN Vol 1: cancer incidence and mortality worldwide (IARC cancerbase number 3). 1998;IARC, Lyon.
2. Walboomers J.M., Jacobs M.V., Manos M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:1999;12-19.
3. Human Papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 64:1995;1-409.
4. Moreno V., Bosch F.X., Munoz N., et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 359:2002;1085-1092.
5. Skegg D.C. Oral contraceptives, parity, and cervical cancer. Lancet. 359:2002;1080-1081.
6. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Hormonal contraception and post-menopausal hormonal therapy. Lyon, International Agency for Research on Cancer. IARC Monogr Eval Carcinog Risks Hum 1999; 72: 49-66 and 339-341.
7. Hildesheim A., Herrero R., Castle P., et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer. 84:2001;1219-1226.
8. Berrington A, Cox DR. Generalised least squares for the synthesis of correlated information. Biostatistics (in press).
9. Cox D.R., Snell E.J. Analysis of binary data. 1989;60 Chapman and Hall, London.
10. Brinton L.A., Huggins G.R., Lehman H.F., et al. Long-term use of oral contraceptives and risk of invasive cervical cancer. Int J Cancer. 38:1986;399-444.
11. Jones C.J., Brinton L.A., Hamman R.F., et al. Risk factors for in situ cervical cancer: results from a case-control study. Cancer Res. 50:1990;3657-3662.
12. Peters R.K., Thomas D., Hagan D., Mack T., Henderson B.E. Risk factors for invasive cervical cancer among Latinas and non-Latinas in Los Angeles County. J Natl Cancer Inst. 77:1986;1063-1077.
13. Ebeling K., Nischan P., Schindler C. Use of oral contraceptives and risk of invasive cervical cancer in previously screened women. Int J Cancer. 39:1987;427-430.
14. Beral V., Hannaford P., Kay C. Oral contraceptive use and malignancies of the genital tract: results from the Royal College of General Practitioners' Oral Contraception Study. Lancet. 2:1988;1331-1335.
15. Irwin K.L., Rosero-Bixby L., Oberle M.W., et al. Oral contraceptives and cervical cancer risk in Costa Rica: detection bias or causal association? JAMA. 259:1988;59-64.
16. Oberle M.W., Rosero-Bixby L., Irwin K.L., et al. Cervical cancer risk and use of DMPA in Costa Rica. Int J Epidemiol. 17:1988;718-723.
17. Brinton L.A., Reeves W.C., Brenes M.M., et al. Oral contraceptive use and risk of invasive cervical cancer. Int J Epidemiol. 19:1990;4-11.
18. Herrero R., Brinton L.A., Reeves W.C., et al. Injectable contraceptives and risk of invasive cervical cancer: evidence of an association. Int J Cancer. 46:1990;5-7.
19. Kjaer S.K., Engholm G., Dahl C., Bock J.E., Lynge E., Jensen O.M. Case-control study of risk factors for cervical squamous-cell neoplasia in Denmark. III. Role of oral contraceptive use. Cancer Causes Control. 4:1993;513-519.
20. Invasive squamous-cell cervical carcinoma and combined oral contraceptives: results from a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer. 55:1993;228-236.
21. Ursin G., Peters R.K., Henderson B.E., d'Ablaing G. 3rd, Monroe K.R., Pike M.C. Oral contraceptive use and adenocarcinoma of cervix. Lancet. 344:1994;1390-1394.
22. Lazcano-Ponce E.C., Hernandez-Avila M., Lopez-Carrillo L., et al. Reproductive risk factors and sexual history associated with cervical cancer in Mexico. Revista de Investigacion Clinica. 47:1995;377-385. (in Spanish).
23. Cuzick J., Sasieni P., Singer A. Risk factors for invasive cervix cancer in young women. Eur J Cancer. 32A:1996;836-841.
24. Daling J.R., Madeleine M.M., McKnight B., et al. The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection. Cancer Epidemiol Biomarkers Prev. 5:1996;541-548.
25. Zondervan K.T., Carpenter L.M., Painter R., Vessey M.P. Oral contraceptives and cervical cancer: further findings from the Oxford Family Planning Association contraceptive study. Br J Cancer. 73:1996;1291-1297.
26. Parazzini F., Chatenoud L., La Vecchia C., Chiaffarino F., Ricci E., Negri E. Time since last use of oral contraceptives and risk of invasive cervical cancer. Eur J Cancer. 34:1998;884-888.
27. Lacey J.V., Brinton L., Abbas F.M., et al. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev. 8:1999;1079-1085.
28. Ylitalo N., Sorensen P., Josefsson A., et al. Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. Int J Cancer. 81:1999;357-365.
29. Deacon J., Evans C.D., Yule R., et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer. 83:2000;1565-1572.
30. Madeleine M.M., Daling J.R., Schwartz S.M., et al. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev. 10:2001;171-177.
31. Berrington A., Jha P.K., Peto J., Green J., Hermon C. Oral contraceptives and cervical cancer. Lancet. 360:2002;410.
32. Bosch F.X., Munoz N., de Sanjose S., et al. Risk factors for cervical cancer in Colombia and Spain. Int J Cancer. 52:1992;750-758.
33. Munoz N., Bosch F.X., de Sanjose S., et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer. 52:1992;743-749.
34. Bosch F.X., Munoz N., de Sanjose S., et al. Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev. 2:1993;415-422.
35. Munoz N., Bosch F.X., de Sanjose S., et al. Risk factors for cervical intraepithelial neoplasia grade III/carcinoma in situ in Spain and Colombia. Cancer Epidemiol Biomarkers Prev. 2:1993;423-431.
36. Eluf-Neto J., Booth M., Munoz N., Bosch F.X., Meijer C.J., Walboomers J.M. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer. 69:1994;114-119.
37. Chaouki N., Bosch F.X., Munoz N., et al. The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer. 75:1998;546-554.
38. Chichareon S., Herrero R., Munoz N., et al. Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst. 90:1998;50-57.
39. Ngelangel C., Munoz N., Bosch F.X., et al. Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst. 90:1998;43-49.
40. Rolon P.A., Smith J.S., Munoz N., et al. Human papillomavirus infection and invasive cervical cancer in Paraguay. Int J Cancer. 85:2000;486-491.
41. Santos C., Munoz N., Klug S.J., et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer. 85:2001;966-971.
42. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception. 45:1992;299-312.
43. Thomas D.B., Ray R.M. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception. 52:1995;307-312.
44. Thomas D.B., Ye Z., Ray R.M. Cervical carcinoma in situ and use of depot-medroxyprogesterone acetate (DMPA). WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception. 51:1995;25-31.
45. Ye Z., Thomas D.B., Ray R.M. Combined oral contraceptives and risk of cervical carcinoma in situ. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol. 24:1995;19-26.
46. Thomas D.B., Ray R.M. Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol. 144:1996;281-289.
47. Author S. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception. 54:(suppl):1996;1S-106S.
48. Green J, Berrington de Gonzalez A, Smith JS, et al. Human papillomavirus and use of oral contraceptives. Br J Cancer (in press).